News

Scientists have discovered that Vav3, a protein that is over-produced in the lining of the lungs of people with cystic fibrosis (CF), promotes lung infections by creating a “docking station” that bacteria such as Pseudomonas aeruginosa use to attach themselves to the lungs. Finding a way to inhibit…

A new technology could enable faster and more accurate cystic fibrosis (CF) diagnoses by non-invasively tracking the movement of air through even the fine structures of the lungs at high-resolution. A study done in mice showed this technology, called X-ray velocimetry (XV), could pinpoint localized areas of abnormal airflow…

Patient dosing has begun in a Phase 1b trial evaluating Calithera Bioscience’s oral therapy CB-280 for cystic fibrosis (CF) patients with chronic airway infections, the company announced. The study (NCT04279769), currently enrolling eligible adults at its two U.S. sites, will test four escalating…

The number of adults with cystic fibrosis (CF) living in the U.K. is expected to increase by at least 28% in 10 years, and 36% of these adults will be older than 40, a study projects. Findings highlight the need to make plans now to care for this changing…

A five-year, $3.2 million grant from the National Institutes of Health (NIH) will fund a  research project that aims to better understand the interactions between bacteria and mucus. Results could help inform new ways of treating diseases where bacterial infections that involve mucus are problematic, such as cystic…

ARINA-1, a nebulized therapy being developed by Renovion for cystic fibrosis (CF) and other chronic inflammatory lung diseases, may be better than currently available options for clearing mucus in CF patients with the most common CFTR mutation, results of a study in cell models of CF showed. The…

Rage Biotech, a new company building on research done at leading Australian universities, aims to develop treatments to help people with chronic inflammatory lung diseases, including cystic fibrosis, severe asthma, and chronic obstructive pulmonary disease. Supported by investments from the IP Group, Monash University, and…

Orkambi (ivacaftor/lumacaftor) can significantly reduce the number of days people with cystic fibrosis (CF) require intravenous antibiotics for flares and helps with weight gain — independently of a patient’s level of lung function at the start of treatment, a real-world study reported. While the greatest lung improvements were…

The common mutations that cause Pseudomonas aeruginosa to lose their ability to move are associated with a higher production of two complex sugar molecules implicated in the formation of biofilms — slimy layers of microorganisms that stick to wet surfaces and protect them from antibiotics and the host’s…

Cystic fibrosis (CF) patients who monitored their lung function at home using NuvoAir‘s handheld spirometer and smartphone app were able to better engage in telemedicine, a U.K. survey found, with these patients reporting a more than 30% drop in their number of scheduled and urgent in-person consultations. The study based…